5 things to know about the 2018 Janssen U.S. Transparency Report
The company just released its third annual report and leaders from across Janssen share some top takeaways, including a new initiative to include the list price and potential out-of-pocket costs for its most frequently prescribed medicine.
Scientists at the Janssen Pharmaceutical Companies of Johnson & Johnson work hard every day at discovering and developing transformational medicines that have the potential to help patients facing some of the world’s most challenging diseases.
To help shed light on what that tireless work entails, the company has just released its 2018 Janssen U.S. Transparency Report, which provides an inside look at how the company invests its resources in the development of new treatments, prices its medicines and helps people who need them get access to them.
In the report, Janssen also shares its ideas for helping to build on what is working in our healthcare system—and for fixing what’s not—as well as details its plan to include the list price and typical patient out-of-pocket costs of a treatment in its U.S. pharmaceutical television advertising.
“We believe enhancing transparency is a positive step toward a more sustainable healthcare system—one that delivers greater access to care, at a more manageable cost,” says Scott White, Company Group Chairman, North America Pharmaceuticals, Johnson & Johnson. “We issue this report because we believe open dialogue and partnership are essential to addressing the challenges patients face.”
For this year’s report rollout, we asked some of Janssen’s top leaders to share their top takeaways.
“The average net price of Janssen’s medicines went down for the second year in a row.”
“Janssen’s research and development investment was significantly more than its spending on sales and marketing.”
“We provided approximately 1 million patients with options to help them get started and stay on the Janssen medicines their healthcare provider prescribed. Out of that number, we helped reduce out-of-pocket costs for approximately 550,000 commercially insured patients.
“Janssen has introduced a new way to help make clearer to patients what they might pay for its medicines.”
“The company helped approximately 1 million people with treatment access, affordability and support—including helping to reduce out-of-pocket costs.”
“Through the Janssen CarePath initiative, we provided approximately 1 million patients with options to help them get started and stay on the Janssen medicines their healthcare provider prescribed. Out of that number, we helped reduce out-of-pocket costs for approximately 550,000 commercially insured patients,” Giordano notes. “Understanding health insurance coverage for medicines can be difficult. As mothers, fathers, caregivers and patients ourselves, we understand the challenges patients may face, and we’re poised to listen and help as best we can.”